Turn Therapeutics enters global supply, license agreement with Medline

Turn Therapeutics (TTRX) announced it has entered into a global supply, development, and license agreement with Medline, the largest provider of medical-surgical products and supply chain solutions serving all points of care. The agreement establishes a long-term collaboration to develop, manufacture, and commercialize products leveraging Turn’s proprietary PermaFusion delivery platform. All financial terms, specific product categories, and development timelines remain confidential in accordance with the terms of the agreement. The Company expects to provide further updates as joint initiatives progress toward commercialization and as development milestones are achieved.